Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 294,462
  • Shares Outstanding, K 102,600
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,410 K
  • 36-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.11
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +7.22%
on 08/08/18
3.26 -11.06%
on 07/17/18
-0.34 (-10.37%)
since 07/16/18
3-Month
2.70 +7.22%
on 08/08/18
3.98 -27.26%
on 05/31/18
-0.44 (-13.32%)
since 05/16/18
52-Week
2.18 +32.80%
on 04/04/18
4.51 -35.81%
on 12/01/17
+0.13 (+4.51%)
since 08/16/17

Most Recent Stories

More News
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2

The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.

VRTX : 175.14 (+1.24%)
SGEN : 74.38 (+0.65%)
CPRX : 2.89 (+0.70%)
GLPG : 101.80 (-1.69%)
Catalyst Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Catalyst Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern...

CPRX : 2.89 (+0.70%)
Catalyst Pharmaceuticals Expands Commercial Leadership Team

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 2.89 (+0.70%)
What's in Store for Catalyst (CPRX) This Earnings Season?

Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.

ENDP : 15.94 (-0.75%)
JAZZ : 173.38 (-0.34%)
CPRX : 2.89 (+0.70%)
PCRX : 46.45 (-3.13%)
BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization

BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today the appointment...

CUR : 1.17 (+1.74%)
BYSI : 19.61 (+1.57%)
CPRX : 2.89 (+0.70%)
Free Research Reports on Catalent and Three More Generic Drugs Stocks

Stock Research Monitor: CPRX, COLL, and DPLO

COLL : 16.46 (+1.67%)
CTLT : 40.82 (+1.01%)
CPRX : 2.89 (+0.70%)
Innovative Biotech Companies, Preparing for the Future

LAS VEGAS, NV / ACCESSWIRE / June 15, 2018 / Some innovative biotechnology companies that are working on ground-breaking technology and are prepared for the future include: Propanc Biopharma, Inc. (OTCQB:...

CLDX : 0.43 (+2.38%)
PPCHD : 1.2000 (+20.00%)
AQXP : 3.05 (+7.02%)
PPCB : 0.0069 (-21.59%)
CPRX : 2.89 (+0.70%)
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 2.89 (+0.70%)
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive...

CUR : 1.17 (+1.74%)
OPNT : 15.50 (-0.13%)
CPRX : 2.89 (+0.70%)
Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

LGND : 240.14 (-2.92%)
ILMN : 327.94 (+0.04%)
BMRN : 100.38 (-1.40%)
CPRX : 2.89 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade CPRX with:

Business Summary

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for...

See More

Key Turning Points

2nd Resistance Point 2.95
1st Resistance Point 2.91
Last Price 2.89
1st Support Level 2.83
2nd Support Level 2.78

See More

52-Week High 4.51
Fibonacci 61.8% 3.62
Fibonacci 50% 3.35
Fibonacci 38.2% 3.07
Last Price 2.89
52-Week Low 2.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar